Marc C Chamberlain1. 1. University of Southern California, Norris Comprehensive Cancer Hospital, Department of Neurology, Los Angeles 90033-0804, USA. chamberl@usc.edu
Abstract
BACKGROUND: A prospective Phase II study of CPT-11 in adult patients with recurrent supratentorial glioblastoma multiforme (GBM). METHODS: Forty patients (25 men, 15 women) ages 32-71 years (median 59), with recurrent GBM were treated. All patients had previously been treated with surgery and involved field radiotherapy (median dose 60 Gy; range 59-60). Additionally, all patients were treated with adjuvant chemotherapy (BCNU in 20, PCV in 18, Procarbazine in 2). Twenty-five patients (62%) were on anticonvulsants (phenytoin in 15, carbamazepine in 10) and 26 patients (65%) were on dexamethasone. Recurrent disease was defined by neuroradiographic disease progression (>25% increase in tumor dimensions) using gadolinium-enhanced MR imaging. The starting dose of CPT-11 was 400 mg/m2 followed in three weeks by 500 mg/m2, operationally defined as one cycle. At week 6, all patients were evaluated with MRI and neurological examination. RESULTS: All patients were evaluable. Two doses (one cycle) of CPT-11 were administered to all patients. CPT-11-related toxicity included: diarrhea (16 patients, 40%); thrombocytopenia (9 patients, 23%); and neutropenia (6 patients, 15%). No patient required transfusion nor was treatment for neutropenic fever required. No treatment-related deaths were observed. All patients demonstrated progressive disease following one cycle of CPT-11. CONCLUSIONS: The lack of response to CPT-11 in this patient group with recurrent GBM suggests either CPT-11 has minimal activity or CPT-11 doses/schedule utilized in this study were sub-optimal. The latter is supported by the modest toxicity seen in this study and the previously documented enhanced clearance of CPT-11 in patients on anticonvulsants and dexamethasone.
BACKGROUND: A prospective Phase II study of CPT-11 in adult patients with recurrent supratentorial glioblastoma multiforme (GBM). METHODS: Forty patients (25 men, 15 women) ages 32-71 years (median 59), with recurrent GBM were treated. All patients had previously been treated with surgery and involved field radiotherapy (median dose 60 Gy; range 59-60). Additionally, all patients were treated with adjuvant chemotherapy (BCNU in 20, PCV in 18, Procarbazine in 2). Twenty-five patients (62%) were on anticonvulsants (phenytoin in 15, carbamazepine in 10) and 26 patients (65%) were on dexamethasone. Recurrent disease was defined by neuroradiographic disease progression (>25% increase in tumor dimensions) using gadolinium-enhanced MR imaging. The starting dose of CPT-11 was 400 mg/m2 followed in three weeks by 500 mg/m2, operationally defined as one cycle. At week 6, all patients were evaluated with MRI and neurological examination. RESULTS: All patients were evaluable. Two doses (one cycle) of CPT-11 were administered to all patients. CPT-11-related toxicity included: diarrhea (16 patients, 40%); thrombocytopenia (9 patients, 23%); and neutropenia (6 patients, 15%). No patient required transfusion nor was treatment for neutropenic fever required. No treatment-related deaths were observed. All patients demonstrated progressive disease following one cycle of CPT-11. CONCLUSIONS: The lack of response to CPT-11 in this patient group with recurrent GBM suggests either CPT-11 has minimal activity or CPT-11 doses/schedule utilized in this study were sub-optimal. The latter is supported by the modest toxicity seen in this study and the previously documented enhanced clearance of CPT-11 in patients on anticonvulsants and dexamethasone.
Authors: I Cokgor; G Akabani; C T Kuan; H S Friedman; A H Friedman; R E Coleman; R E McLendon; S H Bigner; X G Zhao; A M Garcia-Turner; C N Pegram; C J Wikstrand; T D Shafman; J E Herndon; J M Provenzale; M R Zalutsky; D D Bigner Journal: J Clin Oncol Date: 2000-11-15 Impact factor: 44.544
Authors: Zhiyong Liao; Robert W Robey; Josée Guirouilh-Barbat; Kenneth K W To; Orsolya Polgar; Susan E Bates; Yves Pommier Journal: Mol Pharmacol Date: 2007-11-05 Impact factor: 4.436
Authors: Camilo E Fadul; Linda S Kingman; Louise P Meyer; Bernard F Cole; Clifford J Eskey; C Harker Rhodes; David W Roberts; Herbert B Newton; J Marc Pipas Journal: J Neurooncol Date: 2008-07-26 Impact factor: 4.130
Authors: Christina Schaub; Julia Tichy; Niklas Schäfer; Kea Franz; Frederic Mack; Michel Mittelbronn; Sied Kebir; Anna-Luisa Thiepold; Andreas Waha; Natalie Filmann; Mohammed Banat; Rolf Fimmers; Joachim P Steinbach; Ulrich Herrlinger; Johannes Rieger; Martin Glas; Oliver Bähr Journal: J Neurooncol Date: 2016-05-18 Impact factor: 4.130
Authors: Michael D Prados; Kathleen Lamborn; W K A Yung; Kurt Jaeckle; H Ian Robins; Minesh Mehta; Howard A Fine; Patrick Y Wen; Timothy Cloughesy; Susan Chang; M Kelly Nicholas; David Schiff; Harry Greenberg; Larry Junck; Karen Fink; Ken Hess; John Kuhn Journal: Neuro Oncol Date: 2006-03-13 Impact factor: 12.300
Authors: David A Reardon; Patrick Y Wen; Annick Desjardins; Tracy T Batchelor; James J Vredenburgh Journal: Expert Opin Biol Ther Date: 2008-04 Impact factor: 4.388